

Curriculum Vitae

Timothy Devos, MD PhD
(° 22-10-1973)

Hematologist-internist, University Hospitals Leuven, Belgium
Professor at the Faculty of Medicine, University of Leuven, KU Leuven, Belgium.

Timothy.Devos@uzleuven.be

Career

1991-1994: Bachelor degree Medicine at Faculté Notre-Dame de la Paix, Namur (FNDPN)
1994-1998: Master degree Medicine at KU Leuven, Leuven.
1999-2007: Training Internal Medicine (Director: Prof. Dr. J. Fevery) and Hematology (Prof. Dr. M. Boogaerts), University Hospitals Leuven (UZ Leuven) and PhD training (Promotor: Professor Dr Mark Waer)
2007 - now: staff member Hematology UZ Leuven (adjunct-kliniekhoofd)
2008: PhD degree Medical Sciences. «Tolerance and autoimmunity in xenotransplantation». Promotor: Professor Dr Mark Waer. KU Leuven. Grant: Fonds voor Wetenschappelijk Onderzoek (FWO).
2009: Medical Director Cord Blood bank Leuven
2009-now: nomination at the Faculty of Medicine, KU Leuven (deeltijds docent)
2010-now: president Transfusion Committee UZ Leuven and Hemovigilance medical supervisor
2011-now: Medical Director Mesenchymal Stem Cell bank UZ Leuven
2016-now: Director Cord Blood bank Leuven

Research activities, special interests, additional qualifications

2009-now: research in myeloproliferative diseases (MPNs) and CML. PI of several clinical trials at UZ Leuven. Translational projects in collaboration with CME-UZ Leuven (center of genetics).
2010-now: research in cellular therapies (mesenchymal stem cells)
2010-now: research activities in transfusion medicine and hemovigilance in collaboration with nurse-specialists hemovigilance.
2010-now: invited expert at the Belgian Superior Health Council (topic: hematopoietic stem cells)
2011-now: JACIE inspector (quality program hematopoietic stem cell transplantations)

Memberships

Founding member and board member of the BVWB (Belgische Vereniging voor Cel- en Weefselbanken) since 2011.

Member of the Belgian Hematological Society (BHS); chairman MPN subcommittee of BHS; member of Red Blood cell and JACIE subcommittee of BHS

WSN/NVZA ATMP working party: board member since 2012

Member of WSN (Werkgroep stamcellaboratoria Nederland)

Member of EHA (European Hematology Association); member of the EHA Working Party on Myeloproliferative neoplasms (MPN)

Member of ASH (American Society of Hematology)

Reviewer of several international journals:

(some examples as an illustration, list not complete)

- European Journal of Haematology
- Journal of Experimental Pharmacology
- Drugs
- and other journals.

Some peer reviewed publications (of the last years):

(list not complete)

Passamoni F, Griesshammer M, Palandri F, Egyed M, Benevolo G, Devos T, Callum J, Vannucchi A, Sivgin S, Bensasson C, Khan M, Mounedji N, Saydam G. **Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study.** The Lancet Oncology 2017; 18(1): 88-99.

Passamonti F, Giorgino T, Mora B, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Caramazza D, Merli M, Pietra D, Casalone R, Rotunno G, Barbui T, Cazzola M, Vannucchi AM. **A clinical-molecular prognostic model to predict survival in patients with post-polycythemia vera and post essential thrombocythemia myelofibrosis.** Leukemia 2017; 31(12): 2726-2731.

Tefferi A, Al-Ali HK, Barosi G, Devos T, Gisslinger H, Jiang Q, Kiladjian JJ, Mesa R, Passamonti F, Ribrag V, Schiller G, Vannucchi AM, Zhou D, Reiser D, Zhong J, Gale RP. **A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence.** Leukemia 2017; 31(4): 896-902.

Mesa RA, Kiladjian JJ, Catalano JV, Devos T, Egyed M, Hellmann A, McLornan D, Shimoda K, Winton EF, Deng W, Dubowy RL, Maltzman JD, Cervantes F, Gotlib J. **SIMPLIFY-1: A Phase**

III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis. J Clin Oncol. 2017; 35 (34): 3844-3850.

Devos T, Beguin Y, Noens L, Van Eygen K, Zachée P, Mineur P, Knoops L, Doyen C, Theunissen K, Bengiat FS, Reusens M, Pluymers W. **Disease and treatment characteristics of polycythaemia vera patients in Belgium: results from a scientific survey.** Eur J Haematol. 2017 Dec 29. [Epub ahead of print]

Griesshammer M, Saydam G, Palandri F, Benevolo G, Egyed M, Callum J, Devos T, Sivgin S, Guglielmelli P, Bensasson C, Khan M, Ronco JP, Passamonti F. **Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial.** Ann Hematol. 2018 97(9): 1591-1600.

De Roeck L, Michaux L, Debackere K, Lierman E, Vandenberghe P, Devos T. **Coexisting driver mutations in MPN: clinical and molecular characteristics of a series of 11 patients.** Hematology 2018;23(10): 785-792.

Devos T, Meers S, Boeckx N, Gothot A, Deeren D, Chatelain B, Chatelain C, Devalet B. **Diagnosis and management of PNH: Review and recommendations from a Belgian expert panel.** Eur J Haematol 2018; 101(6):737-749.

Barraco D, Mora B, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjan JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Merli M, Pietra D, Barbui T, Rotunno G, Cazzola M, Giorgino T, Vannucchi AM, Passamonti F. **Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project.** Blood Cancer J 2018; 8(10): 89. doi: 10.1038/s41408-018-0128-x. No abstract available.

Demuynck T, Verhoef G, Delforge M, Vandenberghe P, Devos T. **Polycythemia vera and hydroxyurea resistance/intolerance: a monocentric retrospective analysis.** Ann Hematol 2019; 98(6): 1421-1426.

Devos T, Verhoef G, Steel E, Mazure D, Lewalle P, Bron D, Berneman Z, Benghiat FS, Mineur P, Theunissen K, Zachée P, Doyen C, Put N, Lejeune M, Van Eygen K, Havelange V, Reusens M, Pluymers W, Peeters K. **Interruption or Discontinuation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukaemia: A Retrospective Cohort Study (SPARKLE) in Belgium.** Acta Haematol 2019 4: 1-11.

Mora B, Rumi E, Guglielmelli P, Barraco D, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjan JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Cavalloni C, Pietra D, Barbui T, Rotunno G, Cazzola M, Vannucchi AM, Giorgino T, Passamonti F. **Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients.** Cancer Med 2019 Jun 7 [Epub ahead of print].